Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,290 across all filing types
Latest filing 2020-07-17 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
关于控股股东持股减持超过1%的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a formal announcement from Zhengzhou Antu Bioengineering Co., Ltd. regarding a reduction in shareholding by its controlling shareholder, Zhengzhou Antu Industrial Group Co., Ltd. It details the shareholding changes, including the number of shares reduced, the methods of reduction (such as centralized bidding transactions, block trades, and exchangeable bondholder share swaps), and the impact on the controlling shareholder's percentage ownership. The document emphasizes that the reduction does not trigger a takeover bid or change the controlling shareholder. It is a notification about a significant shareholder's shareholding change exceeding 1%. There are no financial statements, earnings data, or management discussion of financial results. The content fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document length is 3011 characters, which is consistent with a detailed announcement but not a full report. Therefore, the appropriate classification is MRQ with high confidence.
2020-07-17 Chinese
关于非公开发行股票申请获得中国证监会受理的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding the acceptance of a non-public stock issuance application by the China Securities Regulatory Commission (CSRC). It mentions the receipt of an administrative license application acceptance notice and states that the approval is pending. The document is brief (458 characters) and serves as an update on a financing activity, specifically a non-public issuance of shares. It does not contain financial statements or detailed financial data, nor is it a full report. Therefore, it fits best under Capital/Financing Update (CAP).
2020-07-15 Chinese
关于控股股东持股减持超过1%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a controlling shareholder's reduction in shareholding exceeding 1%. It details the shareholding changes, dates, and percentages, and explicitly states it is a "提示性公告" (a prompt or indicative announcement) regarding the shareholder's reduction in holdings. There is no financial data, no report attached or referenced as being published, and no mention of financial results or management commentary. The document is a regulatory announcement about shareholding changes, specifically a major shareholding notification. Therefore, the appropriate classification is Major Shareholding Notification (MRQ). The document length is 3032 characters, which is consistent with an announcement rather than a full report.
2020-07-10 Chinese
独立董事关于公司第三届董事会第十五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Zhengzhou Antu Bioengineering Co., Ltd. regarding a board meeting resolution about the use of idle raised funds for cash management. It discusses the legality and appropriateness of using idle raised funds for certain financial products. The document is short (549 characters) and is a statement or opinion related to a board meeting decision, not a full report or financial statement. It does not contain financial data or detailed financial results. This fits best under Board/Management Information (MANG), as it relates to board meeting matters and independent directors' opinions on company decisions.
2020-07-03 Chinese
招商证券关于安图生物使用闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from a sponsoring securities company regarding the use of idle raised funds by a company for cash management. It references regulatory rules about the management and use of raised funds, details the amount and use of the funds, and confirms compliance with relevant laws and procedures. It is not a financial report like an annual or interim report, nor is it an earnings release or a call transcript. It is a formal verification or audit opinion related to the use of funds, which fits the definition of an Audit Report / Information (AR). The document length is under 5,000 characters but contains substantive content and verification opinion, not just an announcement or certification letter, so it is not RPA or RNS. Therefore, the best classification is AR with high confidence. H1 2020
2020-07-03 Chinese
关于使用闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the use of idle raised funds for cash management. It includes specifics about the amount, types of financial products, investment terms, risk control measures, and opinions from independent directors, supervisors, and the sponsor institution. The document references regulatory approvals and compliance with stock exchange rules. It is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. Instead, it is an update on the company's capital management activities related to fundraising proceeds. This fits the definition of a Capital/Financing Update (CAP), as it provides updates on the use of raised funds and related financial activities.
2020-07-03 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.